Beranda › Leukemia Biphenotypic Akut › North Carolina
Uji klinis Leukemia Biphenotypic Akut di North Carolina
11 studi untuk Leukemia Biphenotypic Akut mencari peserta di lokasi di North Carolina.
Kota di North Carolina
Teks studi resmi (Bahasa Inggris)
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
- Carolinas Medical Center/Levine Cancer Institute, Charlotte
- Duke University Medical Center, Durham
- dan 2 lainnya
Menerima pesertaFase 2
365 Days · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT06317662A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
- Duke University Medical Center, Durham
Menerima pesertaFase 1/2
30 Days · Semua jenis kelamin · Diperbarui 16 Sep 2026 · NCT04065399Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Mission Hospital, Asheville
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
- Carolinas Medical Center/Levine Cancer Institute, Charlotte
- dan 4 lainnya
Menerima pesertaFase 3
365 Days – 25 Years · Semua jenis kelamin · Diperbarui 25 Agu 2026 · NCT03959085The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Mission Hospital, Asheville
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
- Carolinas Medical Center/Levine Cancer Institute, Charlotte
- dan 4 lainnya
Menerima pesertaFase 1/2
Hingga usia 22 · Semua jenis kelamin · Diperbarui 25 Agu 2026 · NCT04726241Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)
- Novant Health Presbyterian Hemby Children's Hospital, Charlotte
Menerima pesertaFase 2
Usia 1 hingga 18 · Semua jenis kelamin · Diperbarui 10 Agu 2026 · NCT06390319Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- University of North Carolina at Chapel Hill/ University of North Carolina Medical Center, Chapel Hill
Menerima pesertaFase 1/2
Usia 13 hingga 90 · Semua jenis kelamin · Diperbarui 6 Agu 2026 · NCT06533579Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma
- Novant Health Presbyterian Hemby Children's Hospital, Charlotte
Menerima pesertaFase 4
Usia 1 hingga 18 · Semua jenis kelamin · Diperbarui 14 Jul 2026 · NCT06289673Registry of Older Patients With Cancer
- Seby B. Jones Cancer Center, Boone
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill
- East Carolina University, Greenville
- dan 4 lainnya
Menerima pesertaStudi observasional
Usia 65 ke atas · Semua jenis kelamin · Diperbarui 29 Jun 2026 · NCT01137825A Study of Revumenib and Mezigdomide in People With Leukemia
- University of North Carolina (Data Collection Only), Chapel Hill
Menerima pesertaFase 1/2
Usia 12 ke atas · Semua jenis kelamin · Diperbarui 22 Jun 2026 · NCT07356154Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill
Menerima pesertaStudi observasional
Usia 18 hingga 120 · Semua jenis kelamin · Diperbarui 27 Okt 2025 · NCT01137643Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
- Carolina-Levine Children's Hospital, Charlotte
Menerima pesertaFase 1
Usia 1 hingga 21 · Semua jenis kelamin · Diperbarui 6 Des 2024 · NCT05476770Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.